Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 28, 2021 | Series A | $30M | 1 | — | — | Detail |
Dec 8, 2020 | Angel | $195K | 1 | — | — | Detail |
Mar 1, 2019 | Grant | $798.46K | 1 | National Science Foundation | — | Detail |
Feb 4, 2019 | Non-Equity Assistant | — | 1 | — | — | Detail |
Dec 21, 2017 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |
TBD Angels | — | Series A |
Merck | — | Non-Equity Assistant |